Table 1.

Clinically relevant cell cycle kinase inhibitors.

Targeted kinase	Tumor	Inhibitor	Clinical trials (NCT nUMBER)	Phase	Status
CDK4/6	Liposarcoma (CDK4/6 amp)	Abemaciclib	NCT04967521 [251]	Phase 3	Recruiting
	Sarcoma (CDK4 overexpression/amp)	Palbociclib Palbociclib	NCT03242382NR NCT01209598 [252–254]	Phase 2 Phase 2	Recruiting Completed
	Solid tumors (CDK4/6 amp)	Abemaciclib Palbociclib	NCT03310879 NCT01037790 [252, 255]	Phase 2 Phase 2	Recruiting Completed
	Metastatic breast cancer (HR + ; HER2-)	Abemaciclib + Aromatase Inhibitor / Abemaciclib + Fulvestrant	NCT05362760	Phase 4	Recruiting
	Glioblastoma (CDK4/6 amp)	Abemaciclib Palbociclib	NCT02981940 [256] NCT01227434 [257]	Phase 2 Phase 2	Active Terminated
	Cancer with brain metastasis	Abemaciclib	NCT02308020 [258]	Phase 2	Completed
	Non-Small cell lung cancer	Abemaciclib Abemaciclib + Osimertib	NCT02152631 [259, 260] NCT04545710 [261]	Phase 3 Phase 2	Active Unknown
	Squamous cell lung cancer (CDK4 amp)	Palbociclib + Docetaxel	NCT02785939	Phase 2/3	Completed
	Esophagogastric cancer (CDK6 amp)	Abemaciclib	NCT03292250	Phase 2	Completed
CDK2	Breast cancer and solid tumors	PF-07104091	NCT05262400	Phase 2	Recruiting
ATR	Solid tumors	Berzosertib	NCT03718091 [262]	Phase 2	Completed
	Ovarian cancer	Berzosertib + gemcitabine	NCT02595892 [263]	Phase 2	Active
	Solid tumors (relapsed or refractory)	BAY1895344	NCT05071209	Phase 1/2	Active
	Non-small cell lung cancer	Ceralasertib	NCT05450692	Phase 3	Recruiting
	Advanced solid tumors and Hematological Malignancies	ATG-018	NCT05338346	Phase 1	Recruiting
DNA-PK	Rectal cancer	Peposertib	NCT03770689	Phase 1/2	Completed
CHK1/2	Solid tumors	LY3295368	NCT02873975	Phase 2	Completed
	Small cell lung cancer	LY3295368	NCT02735980	Phase 2	Completed
	Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma	LY2606368	NCT05548296	Phase1/2	Recruiting
WEE1	Triple-negative Metastatic Breast Cancer	MK-1775	NCT03012477	Phase 2	Completed
	Adenocarcinoma of the Pancreas	MK-1775	NCT02037230 [264]	Phase 1/2	Completed
	Advanced solid tumors	Debio 0123	NCT05109975	Phase 1	Recruiting
	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (CycE Driven)	ZN-C3	NCT05128825	Phase 2	Recruiting
	Uterine Serous Carcinoma	ZN-C3	NCT04814108	Phase 2	Recruiting
PLK1	Pancreatic cancer	Rigosertib + Gemcitabine	NCT01360853 [265]	Phase 3	Completed
	Myelodysplastic Syndromes	Rigosertib	NCT01241500 [266]	Phase 3	Completed
AURORA A	Prostate cancer	Alisertib	NCT01799278 [267]	Phase 2	Completed
	Acute Myeloid Leukemia	Alisertib	NCT02560025 [268]	Phase 2	Completed
	Cancer Patients (KRAS G12C mutated)	LY2606368	NCT04956640	Phase 1	Recruiting

In a wide range of tumor malignancies, several kinase inhibitors that target cell cycle regulators are currently undergoing clinical trials for cancer therapy, both as single and combined treatment.